Page 2 - Best Medulloblastoma doctors: TOP 68 doctors

Professor Zvi Ram is a world-renowned neurosurgeon who leads the European Association of Neurosurgical Societies. He is an expert in complex brain tumor surgery and developing innovative gene-based therapies for brain cancer.

• Specializes in neurosurgery for brain tumors and minimally invasive techniques
• Expert in advanced procedures like brain mapping and deep brain stimulation
• Trained internationally in image-guided neurosurgery and microsurgical techniques
• Recipient of the Goldhirsh Foundation Award for innovative neurology treatment
• Treats patients at Sourasky Medical Center (Ichilov) in Israel

Dr. Yildiz has published extensively on neuroendocrine tumors and rare cancers, with research featured in international medical journals.

• Specializes in neuroendocrine tumors and rare cancer cases
• Published 17+ peer-reviewed articles in oncology
• Works at Medipol Mega University Hospital
• Experienced in diagnosing and treating complex oncological cases

Professor Shlomi Constantini is an expert in pediatric neurosurgery, specializing in brain and spine tumors at Sourasky Medical Center.

• 42 years of experience of experience in neurosurgery
• Trained in microneurosurgery and advanced neuro-endoscopy
• Recipient of the Mahaly Best Clinical Research Award from AANS
• Specializes in microsurgical and reconstructive interventions
• Member of multiple international neurosurgical societies

Dr. Dror Levin specializes in pediatric cancers, coordinating sarcoma treatment at Sourasky Medical Center – Israel's leading facility.

• Director of pediatric hematology oncology at Sourasky
• Trained at Rizzoli Orthopaedic Institute – a global leader in bone cancer
• Member of ISPHO (Israel Society of Pediatric Hematology Oncology)
• Specializes in blood disorders and clotting issues in children

Univ. Prof. Dr. Wolfgang Köstler is a leading expert in targeted cancer therapies, with over two decades of experience in medical oncology.

• Specializes in breast cancer and gynecologic malignancies
• Associate Professor at the Medical University of Vienna
• Deputy Head of the Clinical Division of Oncology
• Focuses on individualized systemic cancer therapy and immunotherapy

Professor Keil specializes in advanced imaging techniques for complex cases, including Medulloblastoma, at the Academic Hospital Solingen.

• Graduated with honors from Julius-Maximilians-Universität Würzburg
• Expert in MRI, CT, and ultrasound for precise diagnostics
• Chief Physician of Diagnostic and Interventional Radiology since 2022
• Trained under renowned Professor Rolf W. Günther in Aachen

Prof. Deniz Konya specializes in spinal tumors at Medical Park Göztepe Hospital, with over 76 years of experience of neurosurgical experience.

• Trained at Harvard Medical School's Brigham and Women's Hospital
• Board member of Turkish Spine Society and international spine groups
• Published 47 peer-reviewed papers on spinal treatments
• Performs advanced procedures for spinal fractures and deformities

Assoc. Prof. Nail Paksoy brings specialized expertise in medulloblastoma from his fellowship at Istanbul University Oncology Institute and current role at Medipol Bahçelievler Hospital.

• ESMO Board Certified in Medical Oncology
• Participated in 8 international clinical trials for advanced cancers
• Published multiple peer-reviewed studies on rare cancer treatments
• Completed dual fellowship training in both Medical Oncology and Allergy-Immunology

Dr. Inta Jaunalksne specializes in virotherapy – a cutting-edge approach in immunology with 49 years of experience of experience.

• Head of Clinical Immunology Center at Pauls Stradins Clinical University Hospital
• Graduate of Riga Medical Institute with internship in Internal Medicine
• Focuses on innovative immunology treatments

Specializes in Medulloblastoma with extensive training in medical oncology at Akdeniz University.

• Board-certified in medical oncology since 2018
• Over 20 years of experience of experience in oncology
• Works at Medical Park Antalya Hospital Complex

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.